Accompagnement des projets de R&D en Santé humaine pour optimiser leur développement jusqu'aux patients.Conseils stratégiques et positionnement. Conseils scientifiques et méthodologiques.Gestion de l’enveloppe de preuve de concept Inserm de plus de 1,8M€ par an.Sélection et évaluation scientifique des projets précliniques quelle que soit leur indication.Accompagnement pour le montage de dossiers de soumission auprès de financeurs externes (SATT, Régions, Europe, Fondations, Entreprises pharmaceutiques, ...) Mise en place des partenariats avec les autres structures de l’écosystème de la valorisation de la recherche (SATT, idex, i-site, ...).Montage des consortia lauréats de l'appel Maturation-Prématuration du PIA4 Plan France2030 dans les domaines de la Bioproduction de Biomédicaments, de la Santé numériques et des Maladies Infectieuses Emergentes. Pilotage de la cellule opérationnelle en charge de la coordination des actions de sélection et de financement des projets de thérapie ou diagnostique au stade (pré)maturation et dans l'objectif de redonner à la France sa souveraineté nationale dans ces domaines.

Coordination of maturation process for Inserm projects in France * Managment of Inserm Proof of concept fund - 1 to 2M€/year since 2009 - Processes for Projects detection and selection - Projects programs and budget analysis - Reporting to Inserm * Coordination of partnership with SATTs for maturation programsDetection of Inserm labs innovations (mostly in neurosciences)

In charge of project detection, sourcing, maturation funding.Detection of inventions or specific expertises in Inserm labs.Collaborative work with Inserm Transfert IP Engineer and Business Developpers to categorize these inventions and expertises.Preparation of documentation for presentation to Pharma researchers.Managment of Inserm Transfert processes to help maturation / Preclinical Proof of concept. Funding of research projects dedicated to Preclinical Proof of concept.Project managment.

Manager of preclinical pharmacological studies- Management of the team in charge of antiproliferative molecule screening (Hundreds of molecules have been screened)- Characterization of the molecules in terms of :o mode of action on cancer cell lines (apoptosis, cell cycle, …)o toxicityo PK characteristics- Identification of types of cancer sensitive to these moleculesFollow-up on clinical and ex-vivo studies - Evaluation of the expression level of the target protein in the cells of AML (Acute Myeloïd Leukemia) patients treated with CER0227185- Study of CER0227185 and CER0265876 in vitro antiproliferative and differentiation effects on lymphoid and myeloid precursors purified from AML patient’s blood.

Research EngineerMolecular Engines Laboratories -75 : Development of drugs based on tumor reversionFunctional Characterization of new therapeutic targets : TCTP, Siah and TSAP6 - Development of molecular tools used to generate Knock-Out mice- Comparative study of the phenotypes of mice mutated or null for the TSAP6 protein Study of the transcriptional regulation of the siah-1b gene - Demonstration of the presence and functionality of a P53 binding site in the promoter f the siah-1b gene- Cloning of the total cDNA coding for murine Siah-1b